Clinical trials: COVID-19 Booster
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine…
- Trial name
- COVID-19 (NCT05096832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 18 sites in Malaysia, Pakistan
- Volunteers
- 10,381 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19 Recurrent, Lung Cancer
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients…
- Conditions
- COVID-19 Recurrent, Lung Cancer, Vaccination, Antibody
- Trial name
- NCT06168032
- Testing
- Any Chinese government-recommended COVID-19 booster vaccine
- Where
- China
- Volunteers
- 1,224 people
- Sponsor
- Peking Union Medical College Hospital
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects
This is an open label trial. There will only be 1 group in the study. All subjects will receive INAVAC vaccine and be followed for 6 months. The vaccine will be administered intramuscularly.
- Trial name
- NCT06272253
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
COVID-19
Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults
This Phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of PepGNP-COVID19, a synthetic nanoparticle-based, T cell-priming peptide vaccine against SARS-CoV-2, when administered as a booster dose in…
- Trial name
- NCT07183709
- Testing
- PepGNP-COVID19, Sterile Water for Injection
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as…
- Trial name
- NCT04927065
- Testing
- mRNA-1273.211, mRNA-1273, mRNA-1273.617.2
- Where
- 23 sites in United States
- Volunteers
- 5,161 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Vaccination
Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)
Randomized comparison of 3rd dose with inactivated vaccine (CoronaVac) or mRNA vaccine (Comirnaty) in adults who previously received two doses of CoronaVac (Sinovac) or two doses of BNT162b2 (Comirnaty, BioNTech/Fosun Pharma) at…
- Trial name
- NCT05057169
- Testing
- BNT162b2, CoronaVac
- Where
- Hong Kong
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
COVID-19
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
The purpose of this study is to assess the immunogenicity and safety of SCB-2023B monovalent Omicron XBB.1.5 vaccine compared to the prototype SCB-2019 vaccine in participants previously vaccinated with 3 doses of inactivated…
- Trial name
- NCT06567457
- Testing
- SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Cancer
Booster Dose Trial
The goal of this study is to assess the safety and effectiveness of COVID vaccine booster doses in patients with cancer who have not developed an antibody after the U.S.
- Trial name
- NCT05016622
- Testing
- BNT162b2 vaccine
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Montefiore Medical Center
SARS-CoV2, COVID-19
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended…
- Trial name
- NCT06672055
- Testing
- VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
- Where
- 145 sites in United States
- Volunteers
- 5,485 people
- Sponsor
- Vaxart
COVID-19
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age
The goal of this clinical trial is to evaluate immune response and safety of SARS-CoV-2 subunit protein recombinant vaccine (IndoVac) as a heterologous booster dose in healthy children 12-17 years of age.
- Trial name
- NCT05727215
- Testing
- SARS-CoV-2 subunit protein recombinant vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19 Infection, COVID-19 Vaccine Adverse Reaction
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Booster Vaccine (LEM-mR203) in healthy adults aged at 19 to 55 years
- Trial name
- NCT06032000
- Testing
- LEM-mR203
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lemonex
COVID-19, Vaccine Reaction
Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases
Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2 vaccines than healthy population.
- Conditions
- COVID-19, Vaccine Reaction, Liver Diseases
- Trial name
- NMCIDCHESS2201 (NCT05204602)
- Where
- 19 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
Rheumatoid Arthritis, Psoriatic Arthritis
COVID-19 VaccinE Response in Rheumatology Patients
The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
- Trial name
- COVER (NCT05080218)
- Testing
- Upadacitinib, Abatacept, Secukinumab
- Where
- 8 sites in United States
- Volunteers
- 841 people
- Sponsor
- Jeffrey Curtis
COVID-19
The Phase Ⅱ/Ⅲ Trial of LYB001
The study will be conducted in two phases using a randomized, double-blind, placebo-controlled design. A phase II trial will be initiated to assess the safety of LYB001 as booster shots, and then proceed to a phase III trial to…
- Trial name
- NCT05602558
- Testing
- LYB001
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong
This is a randomized, double-blinded, Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate to evaluate the changes in…
- Trial name
- NCT05254236
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose), COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Coronavirus Infections, Healthy
Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine
NDV-HXP-S is an inactivated COVID-19 vectored-vaccine virus using the Newcastle Disease Virus as basis and expressing Spike (S) protein from SARS-CoV-2 stabilized in pre-fusion form with Hexapro technology.
- Trial name
- Butanvac (NCT05354024)
- Testing
- NDV-HXP-S 10μg, BNT162b2 30μg
- Where
- 6 sites in Brazil
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
COVID-19
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
This is a multicenter, randomized, observer-blinded, active-controlled Phase II study to evaluate the immunogenicity, safety and reactogenicity of the low dose (20μg) and high dose (40μg) of ReCOV, when administered as a booster…
- Trial name
- NCT05323435
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
COVID -19
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults.
- Trial name
- NCT07703475
- Testing
- RVX-sCPD9
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)